Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03012022 · ClinicalTrials.gov registry record
Cleveland Heart and Metabolic Prevention Study
A clinical trial of Heart Failure Risk Factors in Healthy Individuals, sponsored by The Cleveland Clinic.
- Active
- Registry status
- 1,208
- Enrollment target
- 1
- Study location
NCT03012022: Active study of Heart Failure Risk Factors in Healthy Individuals, sponsored by The Cleveland Clinic.
NCT03012022 is a study of Heart Failure Risk Factors in Healthy Individuals that is active but no longer recruiting, run by The Cleveland Clinic. The registered enrollment target is 1,208 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03012022, a study of Heart Failure Risk Factors in Healthy Individuals, is active but no longer recruiting, sponsored by The Cleveland Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 1,208 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to investigate the role of chemical reactions, such as inflammation and oxidation, in the cause of cardiac dysfunction (the heart does not function properly). The investigators are interested in studying the various chemical pathways for cell damage to determine which are the most prevalent and/or most important. The investigators also want to determine whether waste products of oxidative damage or other chemicals can be monitored in the blood or urine and serve as an indication of the existence and severity of overall heart disease activity. The investigators further want to determine whether certain proteins, called enzymes, affect this cell damage, or whether the presence or absence of certain genes which create different forms of these enzymes correlate with the development of heart failure or cardiomyopathy (weakening of the heart muscle or a change in heart muscle structure) or other cardiovascular diseases.
Primary Outcome
Clinical endpoints include acute myocardial infarction, acute coronary syndrome, congestive heart failure, serious cardiac arrhythmia, peripheral vascular disease, cerebrovascular events and death. Events will be aggregated into a common category (e.g. MACE) for statistical analysis and reporting. These aggregated events data will then be correlated with each biomarker of interest.
Conditions Studied
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,208 participants |
| Start Date | 2010-11-08 |
| Est. Completion | 2026-12 |
What the registry record for NCT03012022 still lists
NCT03012022 is an observational study that tracks outcomes without assigning an intervention. Its 1,208 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Heart Failure Risk Factors in Healthy Individuals appearing as the primary indexed condition, and to 0 interventions.
NCT03012022 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03012022 about?
NCT03012022 is a clinical study titled "Cleveland Heart and Metabolic Prevention Study". The purpose of this research study is to investigate the role of chemical reactions, such as inflammation and oxidation, in the cause of cardiac dysfunction (the heart does not function properly). The investigators are interested in studying the various chemical pathways for cell damage to determine...
What is the current status of trial NCT03012022?
This trial is currently active not recruiting. The enrollment target is 1,208 participants. The study started on 2010-11-08. Estimated completion is 2026-12.
What conditions does trial NCT03012022 study?
This clinical trial studies the following conditions: Heart Failure Risk Factors in Healthy Individuals.
Who is sponsoring clinical trial NCT03012022?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03012022 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT06535854 · 1,205 participants · NA
Prevail Global Study
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI